Other Solid Tumors, Pancreatic Neoplasms
Conditions
Brief summary
The purpose of this study is to evaluate the safety, immunogenicity, pharmacodynamics, as well as preliminary efficacy of KRAS neoantigen mRNA vaccine (ABO2102) alone and in combination with toripalimab (anti-PD-1 monoclonal antibody) among participants with KRAS-mutated advanced pancreatic cancer and other solid tumors. The trial includes dose escalation (Part I) and dose expansion(Part II) parts.
Interventions
DRUGABO2102
mRNA encoding mutant KRAS neoantigens, administrated intramuscularly
DRUGToripalimab
Anti-PD-1 antibody, administered intravenously
Sponsors
Suzhou Abogen Biosciences Co., Ltd.
Ruijin Hospital
Study design
Allocation
NON_RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. ≥18 years of age at time of informed consent. 2. Participants with histologically and/ or cytologically confirmed advanced solid tumors (such as pancreatic ductal adenocarcinoma, non-small cell lung cancer, etc.), whose disease has progressed or being intolerant to relevant treatments during or following at least one line of systemic treatment; patients in the second stage include those who have experienced disease progression or intolerance to previous systemic treatments, as well as those who have not received systemic therapy but are deemed by the investigator to potentially benefit from the study treatment based on a comprehensive clinical assessment. 3. Harboring at least one of the targeted KRAS mutants. 4. Eastern Cooperative Oncology Group (ECOG) performance status score of 0\ 2. 5. Life expectancy of ≥12 weeks. 6. Sufficient organ function.
Exclusion criteria
1. Any other prior malignancy active within the previous 5 years, except for skin basal cell cancer that have been cured, superficial bladder cancer, or carcinoma in situ of the breast or cervix. 2. Received KRAS cancer vaccine before. 3. Immunosuppressants or other immunomodulatory drugs were required within 4 weeks before the first dose of study treatment. Physiological doses of systemic steroids or topical medications are allowed. Topical medications should not exceed the dose recommended in the package insert or have any systemic exposure signs; Or patients with other acquired or congenital immunodeficiency diseases, or a history of organ transplantation who need to use immunosuppressants or other immunomodulatory drugs. 4. History of severe allergies or known allergies to any active or inactive component of the study drug(s). 5. Uncontrolled systemic infection; active tuberculosis. 6. Severe cardiovascular diseases. 7. Has known symptomatic, untreated central nervous system metastases, or CNS metastases requiring continued treatment. Participants with asymptomatic brain metastases and who do not require treatment are eligible for enrolment. 8. Have active autoimmune and inflammatory diseases. 9. Have immediate hypersensitivity, a history of eczema or asthma uncontrolled by topical corticosteroids. 10. Have other serious medical conditions 11. A history of organ transplantation, bone marrow transplantation or hematopoietic stem cell transplantation.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Part I: The incidence and nature of dose-limiting toxicity (DLT) for ABO2102 as monotherapy or in combination with toripalilmab. | 21 days after the first dose of study treatment |
| Part I: The incidence and severity of treatment-emergent adverse events (TEAE)s. | from the first dose of study treatment to 30 days after the last dose of monotherapy or to 90 days after the last dose of the combination therapy. |
| Part I: The incidence and severity of serious TEAEs (TESAE)s. | from the first dose of study treatment to 30 days after the last dose of monotherapy or to 90 days after the last dose of the combination therapy. |
| Part I: The incidence and severity of TEAEs leading to interruption or early termination of study treatment. | from the first dose of study treatment to 30 days after the last dose of monotherapy or to 90 days after the last dose of the combination therapy. |
| Part II: Overall Response Rate (ORR) per RECIST version 1.1. | from the first dose of study treatment to up to 2 years. |
Countries
China
Contacts
Primary ContactXinjing Wang
Outcome results
None listed